Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma

Sun, Q (author)

Wang, YJ (author)

Ji, H (author)

Sun, XT (author)

Xie, SS (author)

Chen, LT (author)

Li, S (author)

Zeng, WF (author)

Chen, RB (author)

Tang, Q (author)

Zuo, J (author)

Hou, LK (author)

Lu, YT (author)

Liu, Y (author)

Ye, Y (author)

Yang, YL (author)

(creator_code:org_t)

2022-08-19
2022
English.
In: Cell death & disease. - : Springer Science and Business Media LLC. - 2041-4889. ; 13:8, s. 724-

Related links:: http://kipublication...; show more...; https://doi.org/10.1...; show less...

Abstract Subject headings

Nasopharyngeal carcinoma (NPC) clinical trials show that antiangiogenic drugs (AADs) fail to achieve the expected efficacy, and combining AAD with chemoradiotherapy does not show superiority over chemoradiotherapy alone. Accumulating evidence suggests the intrinsic AAD resistance in NPC patients with poorly understood molecular mechanisms. Here, we describe NPC-specific FGF-2 expression-triggered, VEGF-independent angiogenesis as a mechanism of AAD resistance. Angiogenic factors screening between AAD-sensitive cancer type and AAD-resistant NPC showed high FGF-2 expression in NPC in both xenograft models and clinical samples. Mechanistically, the FGF-2-FGFR1-MYC axis drove endothelial cell survival and proliferation as an alternative to VEGF-VEGFR2-MYC signaling. Genetic knockdown of FGF-2 in NPC tumor cells reduced tumor angiogenesis, enhanced AAD sensitivity, and reduced pulmonary metastasis. Moreover, lenvatinib, an FDA recently approved multi-kinase inhibitor targeting both VEGFR2 and FGFR1, effectively inhibits the tumor vasculature, and exhibited robust anti-tumor effects in NPC-bearing nude mice and humanized mice compared with an agent equivalent to bevacizumab. These findings provide mechanistic insights on FGF-2 signaling in the modulation of VEGF pathway activation in the NPC microenvironment and propose an effective NPC-targeted therapy by using a clinically available drug.

By the author/editor: Sun, Q; Wang, YJ; Ji, H; Sun, XT; Xie, SS; Chen, LT; show more...; Li, S; Zeng, WF; Chen, RB; Tang, Q; Zuo, J; Hou, LK; Hosaka, K; Lu, YT; Liu, Y; Ye, Y; Yang, YL; show less...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.